The 7 Peptides the FDA Reviewed in July 2026 — and What Comes Next
On July 23–24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed seven peptides for possible addition to the 503A bulk compounding list. Only two — BPC-157 and KPV — received favorable votes, and even those were recommendations, not approvals, passed over the objection of FDA staff. (For the full breakdown of what that vote means, see our explainer on the PCAC decision.)
Here is the complete list of what was reviewed, where each one landed, and what comes next. All references below are to laboratory research use only — nothing here is a treatment claim or purchasing advice.
The four reviewed on July 23
1. BPC-157
A synthetic peptide widely studied in preclinical research and long the most-requested compound on the gray market. The panel considered it in the context of gastrointestinal research and voted in favor of adding it to the compounding list. It remains a research-use-only material. LLR carries it in several formats, including a BPC-157 + KPV blend and a BPC-157 + TB-500 blend, or see the research-grade BPC-157 overview.
2. KPV
A short tripeptide fragment of alpha-MSH studied for its role in inflammatory-pathway research. It was the second compound to receive a favorable committee vote. Available in the BPC-157 + KPV blend and the KLOW research kit.
3. TB-500 (Thymosin Beta-4 fragment)
A peptide studied alongside BPC-157 in tissue and recovery research. It did not receive a favorable vote in July. Frequently researched next to BPC-157 — see our BPC-157 vs TB-500 comparison or the combined blend.
4. MOTS-c
A mitochondrial-derived peptide of interest in metabolic research. It did not clear the committee in July. Browse related metabolic research compounds in the full catalog.
The three reviewed on July 24
5. DSIP (emideltide)
Delta sleep-inducing peptide, studied in sleep and stress research. It did not receive a favorable vote. Available as DSIP 5mg.
6. Epitalon
A synthetic tetrapeptide studied in longevity and telomere research. It did not clear the committee in July. Available as Epitalon 10mg.
7. Semax
A peptide studied in cognitive and neuroprotection research. It did not receive a favorable vote. Found in the Semax + Selank research kit.
What comes next
The FDA has signaled that additional peptides are queued for PCAC review before February 2027, so the five compounds that did not clear in July are not necessarily closed cases — they may return with more data. The committee’s recommendations are also non-binding; the FDA has said it will issue final determinations after reviewing the input.
The throughline from the July meeting was data quality: the FDA staff’s objections centered on gaps in characterization, purity, and consistency. For research buyers, that is the same standard that separates usable material from the rest — batch-level, third-party HPLC and mass-spec verification. That is how every compound in our catalog is documented.
Research use only. All peptides referenced are intended solely for in-vitro laboratory research and are not for human or veterinary use, diagnosis, treatment, or consumption. This article is regulatory news and general information, not medical, legal, or purchasing advice.
Sources: FDA Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026; RAPS and Drug Topics coverage; STAT, NPR, and Time reporting.
